Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (37)

2024

  1. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets

    Rheumatology (United Kingdom), Vol. 63, Núm. SI, pp. SI96-SI106

  2. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

    The Lancet HIV, Vol. 11, Núm. 10, pp. e660-e669

  3. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

    Rheumatology (United Kingdom), Vol. 63, Núm. 3, pp. 772-779

  4. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository

    Arthritis and Rheumatology, Vol. 75, Núm. 8, pp. 1407-1414

  2. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

    Laboratory investigation; a journal of technical methods and pathology, Vol. 103, Núm. 6, pp. 100147

  3. Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 984-995

  4. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

    The Lancet Rheumatology

2022

  1. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository

    Arthritis Care and Research, Vol. 74, Núm. 2, pp. 324-335

  2. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Lupus, Vol. 31, Núm. 14, pp. 1770-1776

  3. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

    The Lancet Rheumatology, Vol. 4, Núm. 6, pp. e441-e449

  4. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ( € Registry')

    Lupus Science and Medicine, Vol. 9, Núm. 1

2021

  1. Antiphospholipid antibody profile stability over time: Prospective results from the APS ACTION clinical database and repository

    Journal of Rheumatology, Vol. 48, Núm. 4, pp. 541-547

  2. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository

    Advances in Rheumatology, Vol. 61, Núm. 1

  3. European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 775-781

2020

  1. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry

    Lupus, Vol. 29, Núm. 11, pp. 1353-1363

  2. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339

2019

  1. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1151-1159

  2. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository

    Journal of Thrombosis and Haemostasis, Vol. 17, Núm. 12, pp. 2069-2080

  3. EULAR recommendations for the management of antiphospholipid syndrome in adults

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1296-1304